Lota Zoth, Buffalo Gap, Texas, is a new nominee to the Board of Directors. She has served as a director on the advisory board for the Bank s Abilene Region since 2025. Ms. Zoth is a Certified Public Accountant and was Chief Financial Officer of MedImmune, Inc., a biotechnology company, until its sale to AstraZeneca in 2007. Since then, Ms. Zoth has served as a member of the board of directors of eleven biotechnology product development companies, nine of which either are or were publicly traded. Currently, Ms. Zoth serves on the board of enGene Holdings, Inc. (Nasdaq:ENGN) and Inovio Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company, since January 2018 and August 2018, respectively. For each of these companies, Ms. Zoth also served as chair of the audit committee, designated as a financial expert. She has served these companies in various aspects of board leadership, including board chair and member of compensation, finance, nominating & governance and strategic transaction committees. Ms. Zoth received her B.B.A. in Accounting summa cum laude from Texas Tech University. Qualifications & Experience Ms. Zoth brings significant financial and accounting experience to the Board of Directors having finance experience in biotechnology, technology and not for profit roles. Her tenures as both a public company executive and public company board member will allow a for a unique perspective and experience for oversight of our financial reporting and risk management practices.